CF101

Can-Fite Submits Phase III Protocol Design And Registration Plan To EMA For CF101 To Treat Rheumatoid Arthritis
Mar 21, 2016
Can-Fite BioPharma has submitted to the European Medicines Agency (EMA) a protocol design for its Phase III trial and Registration Plan for the Company's lead compound CF101 in the treatment of rheumatoid arthritis following a ...

Tags: Phase III trail, CF101, Can-Fite
CF101 Drug Released Results From a 24 Week
Jan 2, 2014
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. (OTCBB:OPLI) ...

Tags: Can-Fite BioPharma, OphthaliX, placebo-controlled phase III study
Can-Fite BioPharma Received a Patent Entitled From The European Patent Office
Sep 6, 2013
Can-Fite BioPharma, the parent company of OphthaliX, received a patent entitled ‘Adenosine A3 receptor agonists for the treatment of dry eye disorders including Sjogren’s syndrome’ from the European Patent Office. The ...

Tags: Can-Fite BioPharma